N‐acetylcysteine (1200 mg) showed no clear difference in frequency of crisis (number of pain days) compared with placebo (low certainty).
N‐acetylcysteine (1200 mg) showed no clear difference in severity of pain (maximum pain intensity on pain days) compared with placebo (low certainty).
It is very uncertain whether N‐acetylcysteine (1200 mg) changes qoL of participants living with SCD and their caregivers (measured… compared with placebo (very low certainty).
N‐acetylcysteine (1200 mg) showed no clear difference in adverse effects compared with placebo (low certainty).
N‐acetylcysteine (1200 mg) may leads to lower frequency of hospitalization compared with placebo (low certainty).
It is very uncertain whether N‐acetylcysteine (1200 mg) changes frequency of sickle cell‐related complications (acute chest syndrome) compared with placebo (very low certainty).
N‐acetylcysteine (1200 mg) showed no clear difference in haemoglobin status compared with placebo (low certainty).